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ustin K. Smit, M.Sc.a, Bareld B. Pultrum, M.D.a,
endrik M. van Dullemen, M.D., Ph.D.b, Gooitzen M. Van Dam, M.D., Ph.D.a,
enk Groen, M.D., Ph.D.c, John T.M. Plukker, M.D., Ph.D.a,*
Department of Surgical Oncology, PO Box 30001, 9700 RB, University Medical Center Groningen, University of
roningen, Groningen, The Netherlands; bDepartment of Gastroenterology, University Medical Center Groningen,
niversity of Groningen, Groningen, The Netherlands; and cDepartment of Epidemiology, University Medical Center
roningen, University of Groningen, Groningen, The NetherlandsAbstract
BACKGROUND: High recurrence rates determine the dismal outcome in esophageal cancer. We
reviewed our experiences and defined prognostic factors and patterns of recurrences after curatively
intended transthoracic esophagectomy.
METHODS: Between January 1991 and December 2005, 212 consecutive patients underwent a
radical transthoracic esophagectomy with extended 2-field lymphadenectomy. Recurrence rates, sur-
vival, and prognostic factors were analyzed (minimal follow-up period, 2 y).
RESULTS: Radicality was obtained in 85.6%. The median follow-up period was 26.6 months. The
overall recurrence rate at 1, 3, and 5 years was 28%, 44%, and 64%, respectively, and locoregional
recurrence rate was 17%, 27%, and 43%, respectively. Overall survival rates, including postoperative
deaths, were 45% and 34% at 3 and 5 years, respectively. pT stage and lymph node (LN) ratio greater
than .20 were independent prognostic factors for survival and recurrences. Radicality was most
prognostic for survival, and for N greater than 4 positive LN for recurrences.
CONCLUSIONS: Radicality and LN ratio are strong prognostic factors. High radicality and adequate
nodal assessment are guaranteed by an extended transthoracic approach.















5Annually, more than 1,500 new patients are diagnosed with
sophageal cancer in The Netherlands and 460,000 new pa-
ients worldwide and the incidence still is increasing.1,2 The
Presented at the 2009 Gastrointestinal Cancers Symposium, San Fran-
isco, CA, January 15–17, 2009.
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oi:10.1016/j.amjsurg.2009.12.006umors are difficult to treat as reflected by a relatively low
early rate in curatively intended treated patients of 40%. Over
he years different treatment modalities have been proposed
ut surgical resection remains the mainstay of treatment.3,4
ven with significant advances in the surgical techniques and
erioperative treatment, the 5-year survival rate after curative
ntended surgery rarely is greater than 25%.5 One of the im-
ortant reasons is a relatively high recurrence rate of more than
0% in these patients, leading to an ongoing debate about the

































































































447J.K. Smit et al. Radical esophagectomy and prognostic factorsombined treatment modality, regarding better local tumor
ontrol, prognosis, and survival.6–8
Although the extended 2-field transthoracic esophagec-
omy has been associated with lower locoregional recur-
ences, it has not yet translated into significantly better
urvival compared with the less-extensive transhiatal blunt
issection.9,10 However, a recently performed randomized
utch study by Hulscher et al9 and the updated results
howed a trend toward a better survival for the transthoracic
pproach, even in the distal region.11 The rationale of the
xtended transthoracic method, which is the recommended
rocedure in our center, is to diminish local recurrences by
roviding an optimal local radicality, eradicating regional
micro)metastases, which occur frequently in esophageal
ancer. Therefore, we investigated the impact of radicality
f surgery on survival, patterns of recurrences, and different
rognostic factors in a relatively large, equally staged and
reated, group of patients, who underwent a curatively in-
ended esophageal resection with a standard 2-field lymph-
denectomy in our hospital during a 15-year period.
We compared our data with the results of several large
eries in the literature about the quality of surgery regarding
adicality to obtain better insight in the prognostic factors
or recurrence and survival in these patients.
atients and Methods
atients
Between January 1991 and December 2005, a total of
20 consecutive patients with histologically proven cancer
f the esophagus and gastroesophageal junction underwent
curative intended radical transthoracic resection with an
xtended 2-field lymph node dissection (2-FLND).
The database of these patients included demographic
nformation; tumor characteristics such as tumor size, grade,
istology, stage, therapeutic information; and survival data
ollected prospectively during the follow-up evaluation. In-
ormed consent was obtained in all patients with approval
rom the institutional ethical board. In this study we ex-
luded patients (n  8) with high-grade dysplasia (carci-
oma in situ) from the analyses.
Except from the overall survival calculations, we also
xcluded those with macroscopic irradicality (n  1), the
o-called R2 resections according to the International Union
gainst Cancer Classification,12 and those who died within
0 days or in-hospital (n  9; 4.1%).
Consequently, we analyzed 212 patients in the survival
alculations, most (85%) had adenocarcinomas. Eight of the
0 excluded patients (from recurrences analyses) had stage
II tumors, whereas the other 2 excluded patients had stage
I tumors. Microscopic radical resection (R0) was achieved
n 87% (186 of 212). The average number of resected nodes
as 11 (standard deviation, 8.1; range, 3–61; median, 10).
he median follow-up period was 26.6 months (standard
eviation, 41.1 mo; range; .13–197 mo). cIn the recurrence analyses (n  202), 16 patients (7.9%)
eceived neoadjuvant chemoradiotherapy. The male:female
atio was 4.8:1, with a median age of 63.5 years. In this
roup, 174 patients (86.1%) had an adenocarcinoma and
ost tumors were located in the distal part of the esophagus
55.9%, n 113; Table 1). Generally, the tumors (n 132;
5.3%) were locally advanced T3 or resectable T4 tumors
nd more than half of the patients (56.9%: n  115) had
egional node metastases. Of these patients, 13 (11.3%) had
istant nodal M1a metastasis. The most frequently per-
ormed approach was through a left thoracolaparotomy with
n intrathoracic anastomosis. R0 resection was achieved in
81 patients (181 of 202; 89.6%).
ethods
reoperative staging procedure. The preoperative work-up
onsisted of an endoscopic ultrasonography with eventual
ne-needle aspiration of pathologic nodes that would
hange the preoperative staging (N0 vs N and M0 vs
1a); a 16 to 64 multislice multidetector computed tomog-
aphy (CT) scan of the neck, chest, and abdomen; and ultra-
onography of the cervical region to rule out tumors that were
ocally nonresectable or distant metastases (M1b). Since the
ntroduction of 18F-fluoro-2-deoxy-d-glucose positron emis-
ion tomography (FDG-PET) scan in our hospital (1996), pa-
ients with a T3 or resectable T4 and/or N1 tumor had an
dditional FDG-PET.13 After the clinical work-up all patients
ere discussed at a multidisciplinary panel.
urgical approach. All patients underwent an extended
ransthoracic resection by the same surgical group. The
urgical procedure started with a laparotomy exploring the
eritoneal cavity to exclude distant metastatic disease
M1b) or local nonresectability (T4). Resection was per-
ormed through a left thoracolaparotomy with intrathoracic
nastomosis in case of lower-third esophageal and gastro-
sophageal junction tumors, as categorized by Siewert et
l14 or through a right thoracolaparotomy with cervical
nastomosis in squamous cell tumors and the more proximal
denocarcinomas, including all Barrett tumors.
Routinely, we performed an en bloc esophagectomy with
2-FLND of the mediastinal and abdominal nodes, includ-
ng the nodes at the celiac trunk, along the common hepatic
rtery and upper border of the pancreas, and the para-aortic
egional nodes. Reconstruction usually consisted of a gas-
ric tube, vascularized on the right gastroepiploic vessels, or
colonic substitute in case of previous gastric surgery.
athologic assessment. The resected specimens were ex-
mined according to the standard pathologic procedures.
epth of tumor invasion (pathologic or pT stage), nodal
nvolvement, and distal and proximal resection margins
ere examined routinely and we reported the presence of
ymph/angio invasion and perineural invasion. The 6th
nternational Union Against Cancer Classification/TNM





























448 The American Journal of Surgery, Vol 200, No 4, October 2010atients.15 Based on the prognostic significance in the lit-
rature we also incorporated the number of resected nodes,
he presence of more than 4 positive lymph nodes, and the
atio of positive nodes to the total number of resected lymph
odes in the pathologic staging reports.16
ollow-up evaluation and survival. Patients were followed
p every 3 months for the first postoperative year, every 6
onths for the next year, and then annually for 10 years.
he last follow-up evaluation was in January 2008, ensuring
minimum of 2 years of follow-up evaluation. All data
ere collected prospectively in a patient research database.
Relevant information regarding the follow-up evaluation
as collected from our research database, medical records,
eneral practitioners, and data from the Comprehensive Cancer
Table 1 Clinicopathologic characteristics of patients divided
Characteristic Recurrence (n 
Sex, male/female 99/20 (83.2)







Type of resection, %
Left TT/right TT 63/56 (52.9)
Anastomosis site, %
Intrathoracic/cervical 75/44 (63.0)





Pathologic N stage, %
N0/N1 33/86 (27.7)










4 Positive nodes, %
Yes/no 33/86 (27.7)








GEJ  gastroesophageal junction; SCC  squamous cell carcinoma;
Bolded entries in tables indicate the significant values.enter North Netherlands. The follow-up period was calcu- jated from the time of resection until death from any cause or
ast follow-up evaluation (the overall survival [OS]). Disease-
ree survival was calculated from the time of surgery until
ecurrence, last follow-up evaluation, or death from any cause.
ecurrence definition. Any cytologic or histologic proof,
nequivocal or strong radiologic (CT, magnetic resonance
maging, PET, bone scan, and ultrasonography) suspicious
esions, or obvious clinical evidence of tumor was regarded
s recurrent disease. Recurrences were classified in 3 cate-
ories: local, regional, and distant disease. Depending on
he location of the primary tumor, local recurrence at the
nastomotic site was defined as cancer recurrence at the
nastomosis or at the whole upper mediastinum for upper- and
idesophageal tumors and for distal and gastroesophageal
current and nonrecurrent groups






















































































































449J.K. Smit et al. Radical esophagectomy and prognostic factorsistal mediastinum and hiatal region. Regional recurrence
as defined as nonlocal recurrences within the 2-field area.
istant recurrence was categorized according to the in-
olved organ in hepatic, pulmonary, skeletal, cerebral, skin
r soft tissue, and peritoneal metastases. Any additional
ecurrence found within 6 weeks of the first recurrence was
onsidered to have occurred simultaneously.
reatment of recurrence. Depending on the presenting com-
laints, site, and type of recurrences, treatment was considered
alliative or having curative intent. In case of a localized or
ocoregional recurrence treatment with curative intention was
ffered to the patient whenever possible. The decision to treat
as addressed in a multidisciplinary discussion in close col-
aboration with the surgeon, medical oncologist, gastroenter-
logist, and radiotherapeutic oncologist. As reported previ-
usly by our group, treatment consisted of best supportive care,
adiotherapy alone or combined with chemotherapy, chemo-
herapy alone, or stenting.17 Different combinations of these
reatment modalities also were given. Curatively, intended
adiotherapy usually was given in doses of 50 to 60 Gy and/or
n combination with 5-fluorouracil and cisplatin.
tatistical analysis. Continuous variables were compared
ith the t test and categoric variables were compared with
he chi-square test. Survival and recurrence rates were cal-
ulated according to the Kaplan–Meier method and if ap-
licable were compared using the log-rank test. Univariate
nd multivariate Cox regression analyses were performed to
dentify prognostic factors for survival and recurrent dis-
ase. Factors with a P value of less than .1 in the univariate
nalysis were included in the multivariate Cox regression
nalysis. A P value of less than .05 (95% confidence inter-
al) was considered significant. The statistical analyses
ere performed by using the Statistical Package for Social
ciences (SPSS) version 14.0 software, Chicago, IL.
esults
ecurrences
During the follow-up period recurrent disease was ob-
Table 2 Locoregional recurrence
Primary localization of tumor N (%)
Mid/upper (n  17)
Anastomotic 3 (17.6)
Mediastinal 4 (23.5)




GEJ  gastroesophageal junction.erved in 119 patients (58.9%; Table 1). The diagnosis ofecurrence was based mainly (92%) on radiologic evidence
f disease (CT, magnetic resonance imaging, bone scan,
DG-PET, or ultrasonography) or confirmed by histologic
r cytologic examination during endoscopy. In 10 patients
he diagnosis of recurrent disease was based solely on clin-
cal evidence of disease without further diagnostic exami-
ations.
As shown in Table 1, the 202 patients were divided into
groups; the recurrence group (n  119) and the nonre-
urrence group (n  83). Sex, histology, localization, type
f resection, anastomotic site, M stage, and adjuvant therapy
id not differ significantly between the groups.
Patients with recurrent disease generally were younger
han those without recurrent disease, 62.0 versus 66.7 years
P  .038), respectively. The tumors in the recurrence
roup had a more advanced tumor invasion (pT stage), and
ore often involvement of more than 4 locoregional lymph
odes. In addition, an LN ratio of more than .20 was sig-
ificantly more prevalent in patients with recurrent tumors.
urthermore, perineural and lymphangio invasion were en-
ountered more often, and at pathologic examination a mi-
roscopically involved surgical resection margin (R1) was
ound more often.
The overall recurrence rates at 1, 3, and 5 years after
esection were 28%, 44%, and 64%, respectively, whereas
ocoregional recurrence rates (LRR) occurred in 17%, 27%,
nd 43%, respectively.
Table 2 shows the LRR site classified according to the
rimary tumor localization. Distant recurrent disease (Table 3)
ccurred frequently in the liver (33%) and the skin or soft
issue (40.3%). One of the soft-tissue recurrences was lo-
ated in the orbital region. Cerebral recurrences were diag-
osed relatively often (5.6%).
urvival
The patients (n  212), including those who died post-
peratively (n  9), in this study had a crude OS of 74%,
5%, and 34% after 1, 3, and 5 years, respectively (Fig. 1).
he 10-year OS rate was 27%. When we include only those
ho had a successful resection (n 202), the crude OS rate
as 78%, 47%, and 36% after 1, 3, and 5 years, respec-
ively.
Patients without recurrences had a significantly higher
-year survival rate than those who developed recurrent
isease; 73% and 8%, respectively (Fig. 2; P   .001).
Table 3 Hematogenous recurrence site (n  72)















450 The American Journal of Surgery, Vol 200, No 4, October 2010rognostic factors for survival and recurrent disease
Prognostic factors for survival from the univariate anal-
sis were pT stage (pT2 hazard ratio [HR], 4.7; pT3 HR,
1.4; and pT4 HR, 21.7), pN stage (HR, 3.1), pM stage (HR,
Figure 1 Kaplan–MeieFigure 2 Kaplan–Meier analysis for 202 patients: surv.3), outcome (HR, 2.4), more than 4 positive lymph nodes
HR, 2.3), positive lymph node ratio greater than .20 (HR,
), perineural invasion (HR, 1.8), and lymphangio invasion
HR, 1.7). Independent prognostic factors for survival and
ecurrent disease are displayed in Table 4. Factors that were
































451J.K. Smit et al. Radical esophagectomy and prognostic factorsot significant for both survival and recurrent disease were
N stage, pM stage, outcome, perineural invasion, and lym-
hangio invasion.
Prognostic factors for recurrent disease from the univar-
ate analysis were pT stage (pT2 HR, 5.2; pT3 HR, 13.8;
nd pT4 HR, 20.4), pN stage (HR, 3.5), pM stage (HR, 3.1),
utcome (HR, 2.5), more than 4 positive lymph nodes (HR,
.9), positive lymph node ratio greater than .20 (HR, 3.8),
erineural invasion (HR, 2.3), and lymphangio invasion
HR, 2.1).
Of the dependent factors that are displayed in Table 5,
he pT3/T4, radicality (R0 vs R1), lymph node ratio greater
han .20, and perineural invasion were independent prog-
ostic factors for LRR (Table 6). In both the univariate and
ultivariate analyses pT1 versus pT2 was not significant.
Year of surgery was not prognostic for survival (P 
632) or recurrence (P  .926) in the univariate analyses.
omments
The results of this study show that a transthoracic esoph-
gectomy with 2-FLND provides good disease control in
atients with esophageal cancer. Usually, better results can
e achieved in high-volume centers with experienced sur-
eons generally implementing an uniform treatment policy.
he reported 5-year survival rate in the literature rarely
xceeded 25%.5 In this study the 5-year OS with and with-
ut the postoperative deaths was 34% and 36%, respec-
Table 4 Multivariate Cox regression analysis: independent
prognostic factors for survival (n  212) and recurrent
disease (n  202) after extended esophagectomy for







pT2 3.988 1.361 11.691 .012
pT3 8.518 3.170 24.120 <.001
pT4 17.280 4.447 43.347 <.001
Outcome 1.706 1.071 2.616 .024
Lymph node ratio .20,




pT2 4.287 1.250 14.708 .021
pT3 9.775 3.042 31.416 <.001
pT4 16.625 4.430 62.395 .001
4 Positive lymph
nodes, yes vs no 2.361 1.411 3.952 .001
Lymph node ratio .20,
yes vs no 2.004 1.271 3.159 .003
Bolded entries in tables indicate the significant values.ively, which is in concordance with reported results in other
xperienced centers.9–11,18 Our results confirm that a trans-
horacic extended procedure remains an important curative
ption in the surgical treatment of these patients.
The reported early OS rate at 1 and 3 years as well as the
ate 5- and 10-year OS rates in this study are relatively high
t 74% and 45% and 34% and 27%, respectively. Consid-
ring that most patients (65.3%) had a T3 tumor or higher
tage, the high-grade dysplasia or in situ cancers were ex-
luded but locoregional M1a tumors were included, one
hould agree that these figures are in line with those of
Table 5 Univariate Cox regression analysis: prognostic
factors for locoregional recurrent disease after extended







pT3 11.531 2.765 48.091 .001
pT4 16.596 2.698 102.067 .002
pN stage, negative vs
positive 3.716 2.005 6.889 <.001
pM stage, negative vs
positive, 3.655 1.297 10.304 .014
Outcome, R0 vs R1 4.832 2.533 9.217 <.001
4 Positive lymph
nodes, yes vs no 8.1 4.351 14.967 <.001
Lymph node ratio
.20, yes vs no 5.417 3.017 9.727 <.001
Perineural invasion,
yes vs no 2.907 1.497 5.645 .002
Lymphangio invasion,
yes vs no 3.184 1.773 5.719 .001
Bolded entries in tables indicate the significant values.
Table 6 Multivariate Cox regression analysis: independent
prognostic factors for locoregional recurrent disease after








pT3 6.221 1.424 27.173 .015
pT4 7.627 1.165 49.918 .034
Outcome, R0 vs R1 3.627 1.516 5.901 .002
Lymph node ratio .20,
yes vs no 3.627 1.958 6.717 <.001
Perineural invasion, yes
vs no 2.010 .999 4.047 .050







































































452 The American Journal of Surgery, Vol 200, No 4, October 2010xpert centers. The study by Portale et al19 reported a higher
urvival rate of 50%, but the patient population consisted of
large group of stage I tumors (37%), compared with
3.4% in our study.
The rate of microscopic radicality expressed as a R0
esection was 89.6%, which resulted in a rate of LRR of
1% (n  41) in the resected tumors, which is relatively
ow, particularly in the light of the low number of neoad-
uvant-treated patients in this group (7.9%). Usually the
eported microscopic radicality (R0 resection) rate is be-
ween 57% and 72%.9,20 The relatively high rate of R0
esections in our study (84.9%) can be explained by the
tandard transthoracic surgical procedure with a 2-FLND.
urgeons who routinely performed a transthoracic esopha-
ectomy had better survival outcomes for their patients.21 In
previous reported comparative study in the northern part
f The Netherlands we showed improved treatment results
t the University Hospital in comparison with other teaching
nd nonteaching hospitals in the region.22 Moreover, as
stablished in the present study, the radicality of the surgical
rocedure was an independent prognostic factor for locore-
ional recurrences. This is expected from what is known in
he literature on the effect of R0 resections.8,12 Despite a
igh R0 resection rate the overall 5-year recurrence rate was
isappointing in this and other studies, providing additional
rguments for the use of neoadjuvant treatment modalities.
n the meta-analyses of Gebski et al23 neoadjuvant treatment
as strongly suggested to achieve a higher number of R0
esections, increasing locoregional control. The literature
verview in Table 7 arguments the importance of radicality
R0) obtained by extended surgical resection. Currently,
eoadjuvant chemoradiation contributes considerably in
hese efforts, preventing the occurrence of LRR.
Otherwise, radiotherapy eventually combined with che-
otherapy was considered as the treatment of choice in
ecurrent disease, which was used in 48% of our patients
ith recurrent disease. Studies have shown that aggressive
adiotherapy treatment could be beneficial for survival and
ocal control, reducing dysphagia.24,25 This approach may
Table 7 Literature overview
Study Number of patients Mortality
Mariette et al,18 2003 439 4.5% (in
2.4% (30
Altorki and Skinner,10 2001 111 5.4%
Omloo et al,11 2007
THE 95 2%
TTE 110 7%
Nakagawa,28 2004 171 1.7% (30
Dresner and Griffin,7 2000 176 4% (in-h
2% (30 d
Present study, 2009 212 4.1%
AC  adenoca; SCC  squamous cell cancer; THE  transhiatal rese
*Excluding postoperative mortality.ontribute to the relatively high OS rate in our total study
opulation. The recurrence group consisted of younger pa-
ients (P  .038). An explanation for this observation may
e the presentation of more advanced disease and a delayed
iagnosis.26
The outcome of surgery in patients with a positive lymph
ode ratio (LNR) of more than .20 is a strong prognostic
actor for a worse survival. In a review article Lagarde et
l27 found the LNR and number of positive lymph nodes to
e of strong prognostic value for the survival rate. Depen-
ent prognostic factors for recurrent disease were pT stage,
utcome of surgical margin, more than 4 positive lymph
odes, positive LNR greater than .20, perineural invasion,
nd lymphangio invasion. Independent prognostic factors
or recurrent disease were pT stage, more than 4 positive
ymph nodes, and positive LNR greater than .20.
Our findings show single-institute data for the surgical
reatment of esophageal cancer with good insights into the
rognostic factors for recurrent disease.
A possible weakness of this study was that the follow-up
eriod was based primarily on clinical symptoms followed
y further investigation when necessary and not on rou-
inely based radiologic examinations. Determination of the
oment of recurrent disease as accurately as possible (lead
ime bias) is important for calculating the disease-free sur-
ival used in the regression analysis for recurrent disease.
ecause we did not implement radiologic examinations
outinely during follow-up evaluation our lead time could
e confounding. However, it could be reduced to a mini-
um by including patients in a thorough follow-up scheme.
By incorporation of more than 4 positive lymph nodes
nd more than a .20 positive lymph node ratio into the
taging procedure one can predict the prognoses more ac-
urately and adjust the treatment accordingly. This is not a
ew idea because recently published studies also advocated
o determine these factors routinely.16 We believe that this
tudy adds important information to this concept.
Figure 1 clearly shows the impact of recurrence on sur-
ival (P  .001). It is therefore important to understand
spital and 30 day Histology R0 rate Survival, y
al) AC 17.5% Only R0 3; 54%
5; 41%




Only SCC 96% 5; 55.6%
) AC 64% Only R0 1; 83%
5; 31%
AC 85% 87% 1; 74% (78%)*
3; 45% (47%)
5; 34% (36%)






































453J.K. Smit et al. Radical esophagectomy and prognostic factorshat factors predict recurrence. This study described these
actors and therefore clinicians can predict which patients
re more likely to have a recurrence more accurately than
ased solely on the TNM.
onclusions
Extended radical resections through a transthoracic ap-
roach provide relatively good local control with high early
nd late survival. Nodal involvement, including more than 4
ositive lymph nodes and a LNR greater than .20 are strong
rognostic factors for recurrent disease, particularly locore-
ional recurrences. This study also showed that the quality
f surgery is an independent significant factor affecting both
ecurrences and survival.
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